Skip to content

Evaluating XPERIENCE™ Advanced Surgical Irrigation

Knee Osteoarthritis | Hip Osteoarthritis | Knee Arthritis | Hip Arthritis

A prospective, multi-center, double-arm, parallel, interventional, randomized, controlled clinical trial to assess the rate of periprosthetic joint infection (PJI) in patients undergoing primary total knee arthroplasty (TKA), total hip arthroplasty (THA) or hip resurfacing (HR) with XPERIENCE™ (XP) Advanced Surgical Irrigation versus dilute Betadine (DB).

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Male and female patients aged 18 years or older
2. Diagnosis of osteoarthritis, inflammatory arthritis, osteonecrosis, or post-traumatic arthritis to the affected joint.
3. Primary TKA, THA, and HR
4. Subjects receiving both cemented or uncemented orthopaedic implants
5. Willing and able to sign written consent, follow study protocol and attend follow-up

Exclusion Criteria:

1. Inability or refusal to sign informed consent form
2. Non-English or French speaking, and no licensed translator, family member or substitute decision maker available.
3. Prior arthroplasty procedure to the affected joint
4. Procedures involving solid HA implants
5. Oncologic diagnosis to the affected joint.
6. Non-TKA, THA or HR prosthesis (i.e., hemiarthroplasty, unicompartmental arthroplasty etc.)
7. Allergy to any of the components of XP Advanced Surgical Irrigation
8. Allergy to iodine
9. Presence of concurrent active infection, primary immunodeficiency, history of uncontrolled HIV (CD4 count \<200 cells/uL), treatment with immunomodulatory medications for malignancy or autoimmune disease (with exception to inflammatory arthritis), chronic glucocorticosteroid use (≥20 mg of prednisone daily for at least 1 month with another cause of immunosuppression), and solid organ and/or bone marrow transplantation.
10. History of septic arthritis to the affected joint within two years of surgery(1).
11. History of steroid injection to the affected joint within the three months preceding surgery.
12. Simultaneous bilateral total joint arthroplasty

Study Location

The Ottawa Hospital
The Ottawa Hospital
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Sophie Henke Tarnow

[email protected]
613-737-8899
Jewish General Hospital
Jewish General Hospital
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Laura Epure

[email protected]
London Health Sciences Center
London Health Sciences Center
London, Ontario
Canada

Contact Study Team

Primary Contact

Abbigail Allen

[email protected]
519-685-8500
Hôpital Maisonneuve-Rosemont
Hôpital Maisonneuve-Rosemont
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Serge Marquis

[email protected]
514-252-3400
Humber River Health
Humber River Health
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Michele Petrovic

[email protected]
416-242-1000
McGill University
McGill University
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Karen Smith

[email protected]
University of British Columbia
University of British Columbia
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Raman Johal

[email protected]
St. Joseph's Health Centre
St. Joseph's Health Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Carlos Fernando

[email protected]
416-864-6060 x 46969
CHU de Quebec-Université Laval
CHU de Quebec-Université Laval
Québec, Quebec
Canada

Contact Study Team

Primary Contact

Sylvie Turmel

[email protected]
418-525-4444
Study Sponsored By
Ottawa Hospital Research Institute
Participants Required
More Information
Study ID: NCT05543941